

WEST**End of Result Set**

Generate Collection

L1: Entry 1 of 1

File: USPT

Jul 4, 2000

DOCUMENT-IDENTIFIER: US 6084067 A

TITLE: CTLA4/CD28 ligands and uses therefor

BSPR:

Another embodiment of the invention provides antibodies, preferably monoclonal antibodies, specifically reactive with a peptide of a novel B lymphocyte antigen or fusion protein as described herein. Preferred antibodies are anti-human B7-2 monoclonal antibodies produced by hybridoma cells HF2.3D1, HA5.2B7 and HA3.1F9. These hybridoma cells have been deposited with the American Type Culture Collection at ATCC Accession No. HB11686 (HF2.3D1), ATCC Accession No. HB 11687 (HA5.2B7), and ATCC Accession No. HB11688 (HA3.1F9).

DRPR:

FIGS. 19A-19C depict flow cytometric profiles of cells stained with an anti-hB7-2 monoclonal antibody, HF2.3D1. Cells stained with the antibody were CHO cells transfected to express human B7-2 (CHO-hB7.2), NIH 3T3 cells transfected to express human B7-2 (3T3-hB7.2) and control transfected NIH 3T3 cells (3T3-neo). The anti-hB7.2 antibody B70 was used as a positive control.

DEPR:

Particularly preferred antibodies are anti-human B7-2 monoclonal antibodies produced by hybridomas HA3.1F9, HA5.2B7 and HF2.3D1. The preparation and characterization of these antibodies is described in detail in Example 8. Monoclonal antibody HA3.1F9 was determined to be of the IgG1 isotype; monoclonal antibody HA5.2B7 was determined to be of the IgG2b isotype; and monoclonal antibody HF2.3D1 was determined to be of the IgG2a isotype. Hybridoma cells were deposited with the American Type Culture Collection, which meets the requirements of the Budapest Treaty, on Jul. 19, 1994 as ATCC Accession No. HB11688 (hybridoma HA3.1F9), ATCC Accession No. HB11687 (HA5.2B7) and ATCC Accession No. HB11686 (HF2.3D1).

DEPR:

Supernatants from the hybridomas HA3.1F9, HA5.2B7 and HF2.3D1 were further characterized by competitive ELISA, in which the ability of the monoclonal antibodies to inhibit the binding of biotinylated hCTLA4Ig to immobilized hB7-2 immunoglobulin fusion proteins was examined. Biotinylation of hCTLA4Ig was performed using Pierce Immunopure NHS-LC Biotin (Cat. No. 21335). B7-2 immunoglobulin fusion proteins used were: hB7.2-Ig (full-length hB7-2), hB7.2-VIg (hB7-2 variable domain only) and hB7.2-CIg (B7-2 constant domain only). A hB7.1 -Ig fusion protein was used as a control. For the ELISA, 96 well plates were coated with the Ig fusion protein (50 .mu.l/well of a 20 .mu.g/ml solution) overnight at room temperature. The wells were washed three times with PBS, blocked with 10% fetal bovine serum (FBS), 0.1% bovine serum albumin (BSA) in PBS for 1 hour at room temperature, and washed again three times with PBS. To each well was added 50 .mu.l of Bio-hCTLA4-Ig (70 ng/ml) and 50 .mu.l of competitor monoclonal antibody supernatant. Control antibodies were an anti-B7.1 mAb (EW3.5D12) and the anti-hB7-2 mAb B70 (IgG2bi.kappa., obtained from Pharmingen). The wells were washed again and streptavidin-conjugated horse radish peroxidase (from Pierce, Cat. No. 21126; 1:2000 dilution, 50 .mu.l/well) was added and incubated for 30 minutes at room temperature. The wells were washed again, followed by a 30 minute incubation in 50 .mu.l per well of ABTS in 0.1 M Na-Citrate, pH 4.2 to which a 1:1000

02oct00 08:20:14 User208760 Session D1681.1
 \$0.41 0.117 DialUnits File1
 \$0.41 Estimated cost File1
 \$0.05 TYMNET
 \$0.46 Estimated cost this search
 \$0.46 Estimated total session cost 0.117 DialUnits

File 410:Chronolog(R) 1981-2000 Jul/Aug
 (c) 2000 The Dialog Corporation plc

Set	Items	Description
---	-----	-----
?		
HILIGHT	set on as	' '
HILIGHT	set on as	' '
?	begin	5,73,155,399,357

02oct00 08:20:26 User208760 Session D1681.2
 \$0.00 0.056 DialUnits File410
 \$0.00 Estimated cost File410
 \$0.01 TYMNET
 \$0.01 Estimated cost this search
 \$0.47 Estimated total session cost 0.173 DialUnits

SYSTEM:OS - DIALOG OneSearch
 File 5:Biosis Previews(R) 1969-2000/Oct W1
 (c) 2000 BIOSIS
 File 73:EMBASE 1974-2000/Sep W1
 (c) 2000 Elsevier Science B.V.
 *File 73: Update codes are currently undergoing readjustment.
 For details type Help News73.
 File 155:MEDLINE(R) 1966-2000/Nov W4
 (c) format only 2000 Dialog Corporation
 File 399:CA SEARCH(R) 1967-2000/UD=13314
 (c) 2000 American Chemical Society
 *File 399: Use is subject to the terms of your user/customer agreement.
 RANK charge added; see HELP RATES 399.
 File 357:Derwent Biotechnology Abs 1982-2000/Oct B2
 (c) 2000 Derwent Publ Ltd

Set	Items	Description
---	-----	-----
?	s	(3d1 or hf2(w)3d1) and b7(w)2
	148	3D1
	210	HF2
	148	3D1
	1	HF2(W)3D1
	13085	B7
	7418396	2
	3085	B7(W)2
	S1	1 (3D1 OR HF2(W)3D1) AND B7(W)2
?	t	s1/3/all

1/3/1 (Item 1 from file: 357)
 DIALOG(R)File 357:Derwent Biotechnology Abs
 (c) 2000 Derwent Publ Ltd. All rts. reserv.

0177703 DBA Accession No.: 95-04524 PATENT

Nucleic acids encoding CTLA4/CD28 counter receptor, B7-2 -
specified DNA sequence; expression in host cell culture, tumor cell and
in transgenic mouse; and specific monoclonal antibody produced by a
hybridoma

AUTHOR: Freeman G J; Nadler L M; Gray G S; Greenfield E

PATENT ASSIGNEE: Dana-Farber-Cancer-Inst.; Repligen 1995

PATENT NUMBER: WO 9503408 PATENT DATE: 950202 WPI ACCESSION NO.:
95-075236 (9510)

PRIORITY APPLIC. NO.: US 147773 APPLIC. DATE: 931103

NATIONAL APPLIC. NO.: WO 94US8423 APPLIC. DATE: 940726

LANGUAGE: English